8-K: Ocugen Announces Positive Progress in Gene Therapy Programs and First Quarter 2025 Financial Results

Ocugen reports progress in its gene therapy programs, including OCU400 for retinitis pigmentosa and OCU410ST for Stargardt disease, alongside its first quarter 2025 financial results.

Summary

• Ocugen reported its first quarter 2025 financial results and provided a business update on May 9, 2025.
• The company's OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well, with potential BLA/MAA filings targeted for mid-2026.
• Ocugen anticipates initiating the OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease by mid-2025.
• Positive two-year data from the Phase 1/2 clinical trial of OCU400 for RP showed statistically significant improvement in visual function.
• The OCU410ST Phase 1 clinical trial data demonstrated a 54% slower growth of atrophic lesions at six months in treated eyes compared to untreated eyes.
• Dosing is complete in the Phase 2 portion of the OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA), with 12-month data showing a 4-line gain in visual acuity and 41% slower GA lesion growth in treated eyes.
• All three modifier gene therapies (OCU400, OCU410ST, and OCU410) received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA).
• The first patient was dosed in the Phase 1 clinical trial for OCU200 for diabetic macular edema, with completion of the Phase 1 trial expected in the second half of 2025.
• The company's cash and restricted cash totaled $38.1 million as of March 31, 2025, and they expect the cash runway to last into the first quarter of 2026.
• Total operating expenses for the first quarter of 2025 were $16.0 million, including $9.5 million in research and development expenses.
• Ocugen reported a net loss of $0.05 per common share for the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and regulatory milestones. However, the decrease in cash and net loss temper the overall sentiment.

Positives

• OCU400 Phase 3 trial is progressing well and on track for potential BLA/MAA filings by mid-2026.
• OCU410ST Phase 2/3 trial is anticipated to start by mid-2025.
• Positive long-term safety and efficacy data from OCU400 Phase 1/2 trial.
• OCU410ST Phase 1 data shows slower growth of atrophic lesions.
• OCU410 Phase 1/2 data demonstrates visual acuity gain and slower GA lesion growth.
• ATMP classification granted by the EMA for all three modifier gene therapies, which may accelerate regulatory review.
• First patient dosed in Phase 1 trial for OCU200.
• Collaborative arrangement revenue increased to $1.481 million from $1.014 million in the same quarter last year.

Negatives

• The company reported a net loss of $0.05 per common share for the first quarter of 2025.
• Cash and restricted cash decreased from $58.8 million as of December 31, 2024, to $38.1 million as of March 31, 2025.
• Total operating expenses increased from $13.2 million to $16.0 million compared to the same quarter last year.

Risks

• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from current expectations.
• Clinical trial results may not be indicative of final clinical data.
• Unfavorable new clinical trial data may emerge.
• Earlier non-clinical and clinical data may not be predictive of later clinical trial results.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.
• The company's cash runway is only expected to last into the first quarter of 2026, which may require additional funding.

Future Outlook

Ocugen anticipates meeting its goal of three Biologics License Application (BLA)/Marketing Authorization Application (MAA) filings in the next three years and expects its cash and restricted cash runway into the first quarter of 2026.

Management Comments

• All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologics License Application (BLA)/Marketing Authorization Application (MAA) filings in the next three years, said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
• We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vison.
• We have had a strong start to 2025 and are approaching considerable milestones in the next few months, said Dr. Musunuri.
• I am enthusiastic about where we are as a Company, with a clear and precise business strategy to operate efficiently in service of our patients and shareholders.

Industry Context

Ocugen is focused on gene therapies for blindness diseases, a competitive field with companies like Spark Therapeutics (acquired by Roche) and Novartis also developing gene therapies for retinal diseases. The ATMP classification from the EMA is a significant advantage, potentially accelerating the regulatory review process.

Comparison to Industry Standards

• Ocugen's focus on modifier gene therapies distinguishes it from companies like Novartis and Roche/Spark, which primarily focus on traditional gene therapies or gene editing.
• The 54% slower growth of atrophic lesions in the OCU410ST Phase 1 trial compares favorably to some existing treatments for Stargardt disease, although direct comparisons are difficult due to differing trial designs and endpoints.
• The 4-line gain in visual acuity in the OCU410 Phase 1/2 trial for GA is a promising result, especially considering that current treatments for GA, such as those from Apellis and Iveric Bio, have shown more modest improvements in visual acuity in clinical trials.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful development and commercialization of gene therapies.
• Patients: Access to potentially transformative treatments for blindness diseases.
• Employees: Continued employment and opportunities for professional growth.
• Strategic Partners: Opportunities for collaboration and co-development of therapies.

Next Steps

• Initiate OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease by mid-2025.
• Complete the Phase 1 clinical trial for OCU200 for diabetic macular edema in the second half of 2025.
• Pursue BLA/MAA filings for OCU400 for retinitis pigmentosa by mid-2026.
• Initiate Phase 3 trial for NeoCart contingent on funding and/or partnership.
• National Institute of Allergy and Infectious Diseases intends to initiate a Phase 1 clinical trial for OCU500 in the second quarter of 2025.
• Continue discussions with government agencies and strategic partners regarding developmental funding for its vaccines technology for flu.

Key Dates

Keywords

Ocugen, Gene Therapy, Retinitis Pigmentosa, Stargardt Disease, Geographic Atrophy, OCU400, OCU410ST, OCU410, Clinical Trial, BLA, MAA, ATMP, Financial Results